Get the Stockscreener App
2.26
2.26%
0.05
After Hours:
2.28
0.02
+0.88%
Cardiff Oncology Inc stock is traded at $2.26, with a volume of 379.25K.
It is up +2.26% in the last 24 hours and up +10.24% over the past month.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
See More
Previous Close:
$2.21
Open:
$2.24
24h Volume:
379.25K
Relative Volume:
0.23
Market Cap:
$150.35M
Revenue:
$488.00K
Net Income/Loss:
$-41.44M
P/E Ratio:
-2.4301
EPS:
-0.93
Net Cash Flow:
$-31.47M
1W Performance:
+2.73%
1M Performance:
+10.24%
6M Performance:
-8.50%
1Y Performance:
-14.07%
1-Day Range:
$2.22
$2.28
1-Week Range:
$2.18
$2.47
52-Week Range:
$1.90
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Name
Cardiff Oncology Inc
Sector
Industry
Phone
858-952-7570
Address
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Compare CRDF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.26 | 147.02M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Jun-24-25 | Initiated | Jefferies | Hold |
| Sep-06-24 | Initiated | Craig Hallum | Buy |
| Jan-05-22 | Initiated | William Blair | Outperform |
| Dec-08-21 | Initiated | Robert W. Baird | Outperform |
| Aug-09-21 | Resumed | Maxim Group | Buy |
| Oct-22-20 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Piper Sandler | Overweight |
View All
Cardiff Oncology Inc Stock (CRDF) Latest News
Technical analysis overview for Cardiff Oncology Inc. stockBuy Signal & Precise Swing Trade Alerts - newser.com
Using AI based signals to follow Cardiff Oncology Inc.Portfolio Return Report & Consistent Profit Trade Alerts - newser.com
Is Cardiff Oncology Inc. stock ready for a breakout2025 Valuation Update & High Conviction Buy Zone Alerts - newser.com
What dividend safety score for Cardiff Oncology Inc. stockExit Point & Entry Point Confirmation Signals - newser.com
What technical signals suggest for Cardiff Oncology Inc. stock2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
How to use Fibonacci retracement on Cardiff Oncology Inc.2025 Trading Volume Trends & Community Verified Swing Trade Signals - newser.com
Does Cardiff Oncology Inc. fit your quant trading model2025 Price Momentum & Consistent Growth Stock Picks - newser.com
Blair William & Co. IL Grows Position in Cardiff Oncology, Inc. $CRDF - MarketBeat
Cardiff Oncology to Present at Upcoming Investor Conferences in September - GuruFocus
Is a relief rally coming for Cardiff Oncology Inc. holdersBull Run & Risk Controlled Stock Pick Alerts - newser.com
Analyzing recovery setups for Cardiff Oncology Inc. investorsQuarterly Portfolio Review & AI Driven Price Predictions - newser.com
Measuring Cardiff Oncology Inc.’s beta against major indices2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Why Cardiff Oncology Inc. stock remains resilientJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology at Noble Capital: Promising Results for Onvansertib By Investing.com - Investing.com Canada
Bullish Cardiff Oncology Insiders Loaded Up On US$1.72m Of Stock - simplywall.st
What MACD signals say about Cardiff Oncology Inc.Watch List & Trade Opportunity Analysis Reports - newser.com
Is Cardiff Oncology Inc. a candidate for recovery playMarket Performance Recap & AI Driven Stock Price Forecasts - newser.com
Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) PT at $10.63 - Defense World
Is Cardiff Oncology Inc a good long term investmentMarket Profile Overview & Watch These Before They Go Viral - earlytimes.in
Can Exhicon Events Media Solutions Limited Achieve Revenue Diversification SuccessfullyMarket Timing Techniques & Affordable Market Strategies - earlytimes.in
How supply shortages influence Cardiff Oncology Inc. (XE7C) stockWall Street Watch & Safe Capital Growth Tips - newser.com
Tools to assess Cardiff Oncology Inc.’s risk profile2025 Growth vs Value & Real-Time Volume Triggers - newser.com
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
What technical models suggest about Cardiff Oncology Inc.’s comeback2025 Stock Rankings & Free Real-Time Volume Trigger Notifications - newser.com
Cardiff Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Will Cardiff Oncology Inc. benefit from macro trendsEarnings Performance Report & AI Powered Market Entry Strategies - newser.com
Two Oct. 9 investor presentations: Cardiff Oncology management to appear; webcast replay in 48 hours - Stock Titan
What analysts say about Cardiff Oncology Inc XE7C stockEquity Performance Review & Machine Learning Stock Picks, Daily - earlytimes.in
Cardiff Oncology Inc Stock (CRDF) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cardiff Oncology Inc Stock (CRDF) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
| Levine James E. | Chief Financial Officer |
Dec 17 '24 |
Buy |
5.42 |
2,752 |
14,905 |
65,316 |
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):